Dermal Cell News 3.04 February 6, 2017 | |
| |
TOP STORYInvestigators showed that nonreplicable Cas9/sgRNA ribonucleoproteins can be used to correct genetic defects in skin stem cells of postnatal recessive dystrophic epidermolysis bullosa mice. They developed a method to locally deliver Cas9/sgRNA ribonucleoproteins into the skin of postnatal mice. [Proc Natl Acad Sci USA] Abstract | Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)DERMAL STEM CELLS & TISSUE REGENERATIONReprogramming Postnatal Human Epidermal Keratinocytes toward Functional Neural Crest Fates The authors provide evidence that postnatal human epidermal keratinocytes, in response to FGF2 and IGF1 signals, can be reprogrammed toward a neural crest fate. Genome-wide transcriptome analyses showed that keratinocyte-derived neural crest cells were similar to those derived from human embryonic stem cells. [Stem Cells] Abstract Scientists aimed to compare two different methods that pretended to isolate these two populations: (i) the rapid adhesion method on coated substrate and (ii) the flow cytometry method, which is based on the difference in cell surface expressions of the CD71. They demonstrated that cells isolated by a rapid adherent method are not the same population as keratinocyte stem cells isolated by flow cytometry following α6high/CD71low phenotype. [Int J Mol Sci] Full Article | Graphical Abstract SKIN CANCERS & DISORDERSInvestigators identified the potassium channel inhibitor TRAM-34 as highly effective in combination with vemurafenib. Thus apoptosis was significantly enhanced and cell viability was decreased. [Cell Death Dis] Full Article Increase in the Radioresistance of Normal Skin Fibroblasts but Not Tumor Cells by Mechanical Injury The authors showed that mechanical injury occurring before ionizing radiation decreases radiation-induced cell damage and increases cell repair in normal fibroblasts but not tumor cells in vitro and in vivo. [Cell Death Dis] Full Article Proteochemometric computational methods coupled with kinase assays showed that mebendazole (MBZ) binds and inhibits kinases important in cancer, especially both BRAFWT and BRAFV600E. Researchers found that MBZ synergizes with the MEK inhibitor trametinib to inhibit growth of BRAFWT-NRASQ61K melanoma cells in culture and in xenografts, and markedly decreased MEK and ERK phosphorylation. [Oncotarget] Full Article The objective of this study was to combine two strategies in the same lipid nanocapsules (LNCs): i) gene therapy to modulate anti-apoptotic proteins by the use of Bcl-2 siRNA, and ii) ferrocifens as a new type of anticancer agent. The efficient gene silencing with LNCs was verified by the specific extinction of Bcl-2 in melanoma cells. [Pharmacol Res] Abstract | Graphical Abstract Since the phenotypic characteristics and functional integrity of melanoma stem-like cells (MSLCs) depend on their vascular niche, using a two-dimensional melanoma–endothelium co-culture model, where the MSLC niche was recapitulated in vitro, scientists identified Notch3 signaling pathway as a micro-environmental cue governing MSLC phenotypic plasticity via pathway-specific gene expression arrays. [Lab Invest] Abstract Researchers employed a nano liquid chromatography-tandem mass spectrometry proteomics technology to profile the deep-proteome landscape of WM-266-4 human metastatic melanoma cells. Their advanced melanoma-specific catalogue proved to contain 6,681 unique proteins, which likely constituted the hitherto largest single cell-line-derived proteomic collection of the disease. [PLoS One] Full Article Scientists evaluated the efficacy of a natural agent silibinin to overcome resistance with hedgehog inhibitors in basal cell carcinoma (BCC) cells. Silibinin treatment for 48 hrs strongly inhibited growth and induced death in ASZ001, Sant-1 resistant and GDC-0449 resistant BCC cells. [Photochem Photobiol] Abstract | |
| |
REVIEWSTherapeutic Implications of Cellular and Molecular Biology of Cancer Stem Cells in Melanoma Melanoma treatment becomes difficult and survival is greatly reduced when the patient develop metastasis. Standard conventional oncology treatments such as chemotherapy, radiotherapy and surgical resection are only responsible for shrinking the bulk of the tumor mass and tumor tends to relapse. Thus, targeting cancer stem cells and their microenvironment niche addresses the alternative of traditional cancer therapy. [Mol Cancer] Full Article Visit our reviews page to see a complete list of reviews in the dermal cell research field. | |
| |
INDUSTRY NEWSRealm Therapeutics Submits Investigational New Drug Application for PR022 for Atopic Dermatitis Realm Therapeutics plc announced submission of its first investigational new drug (IND) application to the U.S. Food and Drug Administration for PR022, as a novel treatment for atopic dermatitis. Pending acceptance, the IND will enable Realm to initiate a Phase IIa proof-of-concept trial for patients with atopic dermatitis. [Realm Therapeutics plc] Press Release SpinalCyte, LLC Enrolls First Patient in Landmark Phase I Human Clinical Trial SpinalCyte, LLC announced the enrollment of its first patient in a study for the development of CybroCell, the first dermal fibroblast cell product for treatment of degenerative disc disease. [SpinalCyte, LLC] Press Release | |
| |
POLICY NEWSUS Government Takes Animal-Welfare Data Offline The US Department of Agriculture agency charged with ensuring the humane treatment of large research animals, such as primates and goats, has quietly scrubbed all inspection reports and enforcement records from its website. The move has drawn criticism from animal-welfare and transparency activists who say the public has the right to know how their tax dollars are being used. [Nature News] Editorial Venezuela Is Running Short on HIV Meds—and Places to Turn for Help On top of its currency being in free fall for three years running, empty shelves at supermarkets, and electricity rationing, Venezuela has a serious shortage of medicines, including life-saving anti-HIV drugs. This led a network of Venezuelans living with HIV to seek “urgent humanitarian aid” in June 2016 from the Geneva, Switzerland–based Global Fund to Fight AIDS, Tuberculosis and Malaria. [ScienceInsider] Editorial
| |
EVENTSNEW hPSC Training Course: Reprogramming, Maintenance and Reversion to Naive-Like State NEW Reversion of Primed hPSCs to Naive-Like State Training Course NEW Innovations in Cancer Research and Regenerative Medicine Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Researcher – Inflammation Research (Karolinska Institutet) Postdoctoral Associate – Cancer Biology (University of Florida) PhD Studentships – Skin and Joint Inflammation (Cardiff University) Faculty Member – Melanoma (Oregon Health and Science University) Postdoctoral Fellow – Cutaneous Lymphoma (City of Hope) Bioinformatics Scientist – Cancer Biology (Genentech, Inc.) Principal Scientist – Oncology (Janssen) Tenure-Track Faculty Positions – Department of Biomedical Sciences (University of Pennsylvania) Postdoctoral Research Fellow – Melanoma (Dana-Farber Cancer Institute) Assistant Professor – Molecular Therapeutics of Cancer (Dartmouth College) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Dermal Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|